Current Hypertension Reports

, Volume 8, Issue 1, pp 60–68 | Cite as

Nitrates as adjunct hypertensive treatment



Isolated systolic hypertension (ISH) is an important cause of strokes and heart failure among the elderly, but it is difficult to control in some elderly patients, even with combination antihypertensive therapy. The presence of a prominent reflection wave in the arterial pulse-wave profile of such patients signifies that adjuvant nitrate therapy may prove effective in lowering pulse pressure. This reflection arises in the muscular arteries and is caused by arterial stiffness associated with hypertension and other cardiovascular risk factors, probably including endothelial dysfunction. By acting directly on the arterial wall, nitrates produce endothelium-independent vasorelaxation. The reflection wave and the contribution this makes to pulse pressure are thereby ablated. Controlled trials of the use of isosorbide mononitrate and isosorbide dinitrate in ISH have shown that these agents decrease systolic blood pressure as well as pulse pressure, and with the mononitrate, efficacy appears to be unimpaired by nitrate tolerance.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Weber M: Introduction: hypertension in the elderly. Am J Geriatr Cardiol 2000, 9:11.PubMedGoogle Scholar
  2. 2.
    Franklin SS: Cardiovascular risks related to increased diastolic, systolic and pulse pressure: an epidemiologist’s point of view. Pathol Biol (Paris) 1999, 47:594–603.Google Scholar
  3. 3.
    Perry HM, Davis BR, Price TR, et al.: Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000, 284:465–471.PubMedCrossRefGoogle Scholar
  4. 4.
    Stokes GS: Systolic hypertension of the elderly: pushing the frontiers of therapy—a suggested new approach. J Clin Hypertens 2004, 6:192–197. This review outlines the theoretical basis for using adjuvant nitrate in the management of systolic hypertension.Google Scholar
  5. 5.
    Murrell W: Nitroglycerine as a remedy for angina pectoris. Lancet 1879, 80:80–227.CrossRefGoogle Scholar
  6. 6.
    Duchier J, Iannascoli F, Safar M: Antihypertensive effect of sustained-release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly. Am J Cardiol 1987, 60:99–102.PubMedCrossRefGoogle Scholar
  7. 7.
    Stokes GS, Ryan M: Can extended-release isosorbide mononitrate be used as adjunctive therapy for systolic hypertension? An open study employing pulse-wave analysis to determine effects of antihypertensive therapy. Am J Geriat Cardiol 1997, 6:11–19.Google Scholar
  8. 8.
    Stokes GS, Ryan M, Brnabic A, Nyberg G: A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension. J Hypertens 1999, 17:1767–1773.PubMedCrossRefGoogle Scholar
  9. 9.
    Przewlocka-Kosmala M: [Effect of isosorbide mononitrate on hypotensive action of enalapril in patients with mild and moderate hypertension.]. Pol Merkuriusz Lek 2002, 13:40–42.Google Scholar
  10. 10.
    Stokes GS, Bune AJ, Huon N, Barin ES: Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension. Hypertension 2005, 45:380–384. The main disincentive to the use of nitrates in hypertension has been the expectation that nitrate tolerance would develop; this study indicates that nitrate tolerance is not a problem when certain guidelines are observed.PubMedCrossRefGoogle Scholar
  11. 11.
    Nesbitt SD: Nitrates as adjunct hypertensive treatment: a possible answer to resistant systolic hypertension. Hypertension 2005, 45:352–353.PubMedCrossRefGoogle Scholar
  12. 12.
    Stokes, Barin ES, Gilfillan KL: Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003, 41:297–301. This study shows that ISMN was more effective in decreasing pulse-wave reflection than was angiotensin-converting enzyme inhibition or angiotensin II-receptor blockade.PubMedCrossRefGoogle Scholar
  13. 13.
    Lauer T, Heib C, Preik M, et al.: Reduction in peripheral f low reser ve impairs endothelial function in conduit arteries of patients with essential hypertension. J Hypertens 2005, 23:563–569. This article and Mitchell et al. [14•] show how downstream factors may influence arterial vasoconstriction, and are helpful for understanding how increases in reflection wave amplitude occur.PubMedCrossRefGoogle Scholar
  14. 14.
    Mitchell GF, Parise H, Vita JA, et al.: Local shear stress and brachial artery flow-mediated dilation. The Framingham Heart Study. Hypertension 2004, 44:134–139. This article and Lauer et al. [13•] show how downstream factors may inf luence arterial vasoconstriction, and are helpful for understanding how increases in ref lection wave amplitude occur.PubMedCrossRefGoogle Scholar
  15. 15.
    Doughty JM, Langton PD: A transient dilatation of pressurized rat cerebral arteries during rapid pressure increases is mediated by nitric oxide. Pflugers Arch Eur J Physiol 1998, 436:220–226.CrossRefGoogle Scholar
  16. 16.
    Macha M, Yamazaki K, Gordon LM, et al.: The vasoregulatory role of endothelium derived nitric oxide during pulsatile cardiopulmonary bypass. ASAIO J 1996, 42:M800-M804.PubMedCrossRefGoogle Scholar
  17. 17.
    Stokes GS: A dynamic role of NO in the small artery conduits of the systemic circulation. Physiol Res 2002, 51:57P.Google Scholar
  18. 18.
    Bellien J, Joannides R, Iacob M, et al.: Calcium-activated potassium channels and NO regulate human peripheral conduit artery mechanics. Hypertension 2005, 46:210–216.PubMedCrossRefGoogle Scholar
  19. 19.
    Kojda G, Harrison DG: Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999, 43:562–571.PubMedCrossRefGoogle Scholar
  20. 20.
    Pauca AL, Kon ND, O’Rourke MF: Benefit of nitroglycerin on arterial stiffness is directly due to effects on peripheral arteries. Heart 2005, 91:1428–1432.PubMedCrossRefGoogle Scholar
  21. 21.
    Safar ME, O’Rourke MF: Pulse pressure and antihypertensive agents. Hypertension 2005, 46:e6.PubMedCrossRefGoogle Scholar
  22. 22.
    Panza JA, Quyyumi AA, Brush JE, et al.: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22–27.PubMedCrossRefGoogle Scholar
  23. 23.
    Brosnan MJ, Hamilton CA, Graham D, et al.: Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. J Hypertens 2002, 20:281–286.PubMedCrossRefGoogle Scholar
  24. 24.
    Schiffrin EL, Deng Li-Y: Comparison of effects of angiotensin I-converting enzyme inhibition and [beta]-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995, 25:699–703.PubMedGoogle Scholar
  25. 25.
    Ghiadoni L, Magagna A, Versari D, et al.: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003, 41:1281–1286.PubMedCrossRefGoogle Scholar
  26. 26.
    Kiowski W, Linder L, Nuesch R, et al.: Effect of cilazopril on vascular structure and function in essential hypertension. Hypertension 1996, 27:371–376.PubMedGoogle Scholar
  27. 27.
    Rizzoni D, Muiesan ML, Porteri E, et al.: Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J Hypertens 1997, 15:197–204.PubMedCrossRefGoogle Scholar
  28. 28.
    Van der LindeNAJ, Boomsma F, van der MeirackerAH: Role of nitric oxide in modulating systemic pressor responses to different vasoconstrictors in man. J Hypertens 2005, 23:1009–1015.PubMedGoogle Scholar
  29. 29.
    Taddei S, Grassi G: Angiotensin II as the link between nitric oxide and neurogenic function. J Hypertens 2005, 23:935–937.PubMedCrossRefGoogle Scholar
  30. 30.
    Brunner H, Cockcroft JR, Deanfield J, et al.: Endothelial function and dysfunction. Part II; Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:233–246.PubMedCrossRefGoogle Scholar
  31. 31.
    Franklin SS, Gustin WIV, Wong ND, et al.: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997, 96:308–315.PubMedGoogle Scholar
  32. 32.
    Duggirala MK, Cuddihy RM, Cuddihy M-T, et al.: Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005, 18:833–838. In this retrospective study, therapeutic use of nitrates is shown to be a strong predictor of well-controlled blood pressure.PubMedCrossRefGoogle Scholar
  33. 33.
    Taylor AL, Ziesche S, Yancy C, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049–2057. This provides impressive clinical trial evidence that NO donors increase survival in heart failure.PubMedCrossRefGoogle Scholar
  34. 34.
    Persu A, Vinck WJ, El Khattabi OE, et al.: Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: sib-pair analysis and haplotype study. J Hypertens 2005, 23:759–765.PubMedCrossRefGoogle Scholar
  35. 35.
    Yamashita T, Kawashima S, Ohashi Y, et al.: Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice over-expressing endothelial nitric oxide synthase. Hypertension 2000, 36:97–102.PubMedGoogle Scholar
  36. 36.
    Li R, Lyn D, Lapu-Bula R, et al.: Relation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function, and blood pressure in African-Americans. Am J Hypertens 2004, 17:560–567.PubMedCrossRefGoogle Scholar
  37. 37.
    Starmans-Kool MJ, Kleinjans HA, Lustermans FA, et al.: Treatment of elderly patients with isolated systolic hypertension with isosorbide in an asymmetric dosing schedule. J Hum Hypertens 1998, 12:557–561.PubMedCrossRefGoogle Scholar
  38. 38.
    Felizardo A, Maldonado J, Pego M, et al.: Role of nitrates in pharmacologic modulation of reflected waves and their significance in the treatment of arterial hypertension of the elderly. Rev Port Cardiol 1997, 16:607–611.PubMedGoogle Scholar
  39. 39.
    Stokes GS, Barin ES, Gilfillan KL, Kaesemeyer WH: Interactions of L-arginine, isosorbide mononitrate and angiotensin II inhibition on arterial pulse wave. Am J Hypertens 2003, 16:719–724.PubMedCrossRefGoogle Scholar
  40. 40.
    Tingberg E, Roijer A, Thilen U, et al.: Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 2003, 145:E1.PubMedCrossRefGoogle Scholar
  41. 41.
    Muller S, Konig I, Meyer W, Kojda G: Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol 2004, 44:624–631.PubMedCrossRefGoogle Scholar
  42. 42.
    O’Rourke MF, Safar ME: Relationship between aortic stiffening and microvascular disease in brain and kidney. Cause and logic of therapy. Hypertension 2005, 46:200–204.PubMedCrossRefGoogle Scholar
  43. 43.
    Allbutt C: Senile plethora or high arterial pressure inelderly persons. In Classic Papers in Hypertension, Blood Pressureand Renin. Edited by Swales JD. London: Science Press; 1987:104–123.Google Scholar
  44. 44.
    Bitar F, Akhter MW, Khan H, Elkayam U: Survey of the use of organic nitrates for the treatment of chronic congestive heart failure in the United States. 2004, 94:1465–1468.Google Scholar
  45. 45.
    Nyberg G: Current status of isosorbide-5-mononitrate therapy in chronic stable angina pectoris. Am J Ther 1994, 1:93–101.PubMedCrossRefGoogle Scholar
  46. 46.
    Stokes GS, Ryan M: Can extended-release isosorbide mononitrate be used as adjunctive therapy for systolic hypertension? An open study employing pulse-wave analysis to determine effects of antihypertensive therapy. Am J Geriatr Cardiol 1997, 6:11–19.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Mona ValeAustralia

Personalised recommendations